1-8 of 8
Michael A. Levine, MD, ML, MACE
Aliya Khan, MD, FRCPC, FACP, FACE, FASBMR
Future-Proofing in HAE: Advances in Long-term Prophylaxis to Prevent Attacks and Improve Quality of Life
CME/CEFuture-Proofing in HAE: Advances in Long-term Prophylaxis to Prevent Attacks and Improve Quality of Life
Marc A. Riedl, MD, MS
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
Therapeutic Options for ADH1 and Hypoparathyroidism
MinuteCE®Therapeutic Options for ADH1 and Hypoparathyroidism
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
Increasing ADH1 Awareness: A Hidden Cause of Hypoparathyroidism
MinuteCE®Increasing ADH1 Awareness: A Hidden Cause of Hypoparathyroidism
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
Emerging Therapeutics in ADH1: Progress in Precision Medicine
MinuteCE®Emerging Therapeutics in ADH1: Progress in Precision Medicine
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
- advertisement
CASR and ADH1: Integrating Biology and Genetic Screening
MinuteCE®CASR and ADH1: Integrating Biology and Genetic Screening
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
Case Management Strategies for Patients with ADPKD – Part 2
CME/CECase Management Strategies for Patients with ADPKD – Part 2
Frederic Rahbari-Oskoui, MD, MSc
